Emergency medicine and battlefield care may soon receive a technological boost following FDA clearance of the first AI system specifically designed to detect absent lung sliding on ultrasound images. Deep Breathe Inc., a medical diagnostic software company based in London, Ontario, announced the regulatory milestone for its AI tool that identifies a key indicator of pneumothorax—a potentially life-threatening condition where air leaks into the space around the lung.

The clearance marks Deep Breathe's second FDA authorization within 12 months, positioning the company in the specialized field of lung ultrasound artificial intelligence. For clinicians working in emergency departments, ambulances, and field settings, the technology is designed to act as a decision support tool when time-sensitive diagnosis is critical and imaging expertise may be limited.

Bridging the Expertise Gap in Point-of-Care Settings

Absent lung sliding serves as a warning sign of pneumothorax, but recognizing this subtle ultrasound finding requires skill that many frontline providers lack. Deep Breathe's patented AI technology has been evaluated at bedside across multiple hospitals and is designed to work with portable ultrasound devices in emergency rooms, ambulances, and field environments.

According to the company, the system addresses a gap in point-of-care ultrasound interpretation, particularly for clinicians with limited imaging experience. When pneumothorax goes unrecognized, delayed treatment can prove fatal—making rapid, accurate detection essential in trauma and emergency care scenarios.

From Emergency Rooms to Military Operations

Deep Breathe's strategy extends beyond traditional healthcare settings into defense applications. The company was selected for NATO DIANA's Mission Track defense innovation program and has received $1 million in Canadian federal funding to support its development efforts.

A related application has been tested with U.S. Marine Corps medical personnel who had limited ultrasound experience. According to Deep Breathe, the military validation demonstrated improved image interpretation accuracy, suggesting the AI could prove valuable in combat casualty care where specialized radiologists are unavailable.

Dr. Robert Arntfield, the company's Founder and CEO, leads the organization from its headquarters in London, Ontario, with additional locations in Toronto and Boston. The regulatory success—two FDA clearances in one year—combined with NATO partnership and military validation data indicates Deep Breathe is developing a position in this diagnostic AI niche.

Looking Ahead

The clearance arrives as point-of-care ultrasound becomes increasingly prevalent in emergency and prehospital settings, yet interpretation challenges remain a barrier to optimal use. Deep Breathe's technology represents an attempt to expand diagnostic capabilities, potentially allowing providers with varying skill levels to make more confident clinical decisions when time is critical.

With regulatory approval secured, the company now faces the challenge of demonstrating real-world clinical impact and establishing market penetration across both healthcare and defense sectors.

Sources

  1. Deep Breathe Receives FDA Clearance for the First AI Dedicated to Detecting Absent Lung Sliding — EIN Presswire